CD8A and neoplasm: Upon examining the tumor-immune infiltrate from B16 tumors after 10 days of treatments, we observed an increase in CD8+ and CD4+ Teffs in the combination treatment group that was not detectable in either monotherapy treatment group (Figure 6, B–E).